Assembly Biosciences, Inc.: 10-Q filed 2013-08-09

Name: Assembly Biosciences, Inc.: 10-Q filed 2013-08-09
Creator: Assembly Biosciences, Inc.

What Assembly Biosciences, Inc. reported in its quarterly report filed 2013-08-09 (fiscal Q2 2013): 22 published measures, 66 facts as tagged in accession 0001144204-13-044388.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-08-09
Fiscal period: fiscal Q2 2013
Accession: 0001144204-13-044388 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Assembly Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-06-30	33,676,769	USD
At 2012-12-31	20,555,644	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2013-06-30	2,585,383	USD
At 2012-12-31	2,745,458	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2013-06-30	31,091,386	USD
At 2012-12-31	17,810,186	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-06-30	33,489,917	USD
At 2012-12-31	20,489,219	USD
At 2012-06-30	28,843,880	USD
At 2011-12-31	36,975,434	USD
At 2005-10-06	0	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-4,751,888	USD	91
2013-01-01 to 2013-06-30	-8,474,983	USD	181
2005-10-07 to 2013-06-30	-100,794,497	USD	2824
2012-04-01 to 2012-06-30	-7,470,048	USD	91
2012-01-01 to 2012-06-30	-15,643,924	USD	182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	-7,748,554	USD	181
2005-10-07 to 2013-06-30	-69,566,644	USD	2824
2012-01-01 to 2012-06-30	-13,025,130	USD	182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	5,166	USD	181
2005-10-07 to 2013-06-30	47,630	USD	2824
2012-01-01 to 2012-06-30	3,240	USD	182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	20,754,418	USD	181
2005-10-07 to 2013-06-30	103,104,191	USD	2824
2012-01-01 to 2012-06-30	4,896,816	USD	182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	-5,166	USD	181
2005-10-07 to 2013-06-30	-47,630	USD	2824
2012-01-01 to 2012-06-30	-3,240	USD	182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2013-06-30	9,329	USD
At 2012-12-31	6,841	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	979,575	USD	181
2005-10-07 to 2013-06-30	9,751,497	USD	2824
2012-01-01 to 2012-06-30	1,540,553	USD	182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-4,808,759	USD	91
2013-01-01 to 2013-06-30	-8,577,727	USD	181
2005-10-07 to 2013-06-30	-87,207,534	USD	2824
2012-04-01 to 2012-06-30	-7,478,306	USD	91
2012-01-01 to 2012-06-30	-15,668,363	USD	182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-06-30	33,667,440	USD
At 2012-12-31	20,548,803	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-06-30	2,131,673	USD
At 2012-12-31	1,847,245	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	3,508,450	USD	91
2013-01-01 to 2013-06-30	6,117,553	USD	181
2005-10-07 to 2013-06-30	65,160,959	USD	2824
2012-04-01 to 2012-06-30	6,161,924	USD	91
2012-01-01 to 2012-06-30	12,584,650	USD	182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-06-30	19,604,350	shares
At 2012-12-31	12,934,350	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-06-30	131,497,309	USD
At 2012-12-31	110,116,766	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2013-06-30	453,710	USD
At 2012-12-31	898,213	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	1,300,309	USD	91
2013-01-01 to 2013-06-30	2,460,174	USD	181
2005-10-07 to 2013-06-30	22,046,575	USD	2824
2012-04-01 to 2012-06-30	1,316,382	USD	91
2012-01-01 to 2012-06-30	3,083,713	USD	182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	2,678	USD	181
2005-10-07 to 2013-06-30	38,301	USD	2824
2012-01-01 to 2012-06-30	2,083	USD	182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	0	USD	91
2005-10-07 to 2013-06-30	-13,850,826	USD	2824
2012-04-01 to 2012-06-30	0	USD	91

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2013-02-01 to 2013-02-28	20,800,000	USD	28
2012-01-01 to 2012-12-31	4,200,000	USD	366

Inspect the source

Entity: Assembly Biosciences, Inc. / CIK 0001426800
Captured: 2026-09-20T08:03:55.156Z
SEC response SHA-256: f87ee3d44f43bd73d30c280e8d97b2de4bcc4d8a35b03fbebb0e715c83069335

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001426800.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))